Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lenalidomide
Drug ID BADD_D01253
Description Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties.[A228553] It is a 4-amino-glutamyl analogue of [thalidomide] [A228543] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms.[A228708] However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity.[A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma in selected patients.[L16028] Lenalidomide is available only under a special restricted distribution program.[A228708]
Indications and Usage Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Marketing Status Prescription
ATC Code L04AX04
DrugBank ID DB00480
KEGG ID D04687
MeSH ID D000077269
PubChem ID 216326
TTD Drug ID D0Q5NX
NDC Product Code 59572-415; 59572-402; 55488-0700; 0480-1242; 0480-1244; 14096-131; 65727-084; 0480-1246; 59572-420; 59116-4710; 59572-425; 53104-7720; 59572-410; 55111-911; 68554-0090; 71796-026; 0480-1243; 46708-927; 59572-405; 53104-7726; 54893-0061; 82245-0101; 65015-772
Synonyms Lenalidomide | 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione | 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)- | IMiD3 Cpd | CC 5013 | CC5013 | CC-5013 | Revlimid | Revimid
Chemical Information
Molecular Formula C13H13N3O3
CAS Registry Number 191732-72-6
SMILES C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dizziness postural02.01.02.005; 24.06.02.008; 17.02.05.0040.015054%Not Available
Drooling17.02.05.005--Not Available
Drug eruption23.03.05.001; 08.01.06.015; 10.01.01.005--Not Available
Drug hypersensitivity10.01.01.001--Not Available
Drug withdrawal syndrome19.07.02.011; 08.06.02.004--Not Available
Dry eye06.08.02.0010.047477%
Dry mouth07.06.01.002--
Dry skin23.03.03.0010.174276%
Dry throat22.02.05.004; 07.06.01.0050.011001%Not Available
Duodenal ulcer07.04.02.002--
Duodenal ulcer haemorrhage24.07.02.020; 07.04.02.004--Not Available
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia17.02.07.003; 07.14.03.0010.184119%
Dyskinesia17.01.02.006--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.0040.091481%
Dyspnoea22.02.01.004; 02.01.03.002--
Dyspnoea exertional22.02.01.005; 02.01.03.003--Not Available
Dysuria20.02.02.002--
Ear disorder04.03.01.0010.007527%Not Available
Ear haemorrhage24.07.01.004; 04.03.01.002--Not Available
Ear infection11.01.05.001; 04.03.01.0060.030687%Not Available
Ear pain04.03.01.0030.022002%
Ear swelling04.03.01.0140.009264%Not Available
Eating disorder19.09.01.008; 14.03.01.008--Not Available
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Eczema23.03.04.006--
Ejaculation disorder21.03.01.002--
Electrocardiogram abnormal13.14.05.001--Not Available
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 70 Pages